Biogen Idec has announced that Richard A. Rudick, M.D., has joined the company as vice-president, Development Sciences, Value-Based Medicine. He will lead Biogen Idec's newly created Value-Based Medicine Group, which will focus on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). These assets are intended to enable physicians and patients to make more evidence-based, individualized treatment decisions with the goal of improving MS care. He will report to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.

Dr. Rudick joins Biogen Idec from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years. He also served as professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, the Hazel Prior Hostetler chair of Neurology, and vice chairman of research and development in the Neurological Institute at Cleveland Clinic.

Dr. Rudick has lectured and consulted on clinical research programs in MS around the world and maintained a consultative clinical practice at the Mellen Center. He also maintained continuous competitive grant funding from the National Institutes of Health and the National Multiple Sclerosis Society for more than 25 years, led studies on immunologic changes in MS patients, and developed new clinical and imaging measures for MS clinical trials. Dr. Rudick graduated from Case Western Reserve University School of Medicine in 1975.

Source: Biogen Idec